Literature DB >> 11016658

Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact.

L Girnita1, A Girnita, B Brodin, Y Xie, G Nilsson, A Dricu, J Lundeberg, J Wejde, A Bartolazzi, K G Wiman, O Larsson.   

Abstract

We investigated the functional impact of p53 on insulin-like growth factor I receptor (IGF-IR) expression in malignant cells. Using the BL-41tsp53-2 cell line, a transfectant carrying temperature-sensitive (ts) p53 and endogenous mutant p53 (codon 248), we demonstrated a drastic down-regulation of plasma membrane-bound IGF-IRs on induction of wild-type p53. However, a similar response was obtained by treatment of BL-41tsp53-2 cells expressing mutant ts p53 with a p53 antisense oligonucleotide. Thus, even if the negative effect of wild-type p53 predominates under a competitive condition, these data indicate that mutant p53 may be important for up-regulation of IGF-IR. To further elucidate this issue, three melanoma cell lines (BE, SK-MEL-5, and SK-MEL-28) that overexpressed p53 were investigated. The BE cell line has a "hot spot" mutation (codon 248) and expresses only codon 248-mutant p53. SK-MEL-28 has a point mutation at codon 145. SK-MEL-5 cells did not exhibit any p53 mutations, but the absence of p21Waf1 expression suggested functionally aberrant p53. Our data suggest that interaction with Mdm-2 may underlie p53 inactivation in these cells. Using p53 antisense oligonucleotides, we demonstrated a substantial down-regulation of cell surface expression of IGF-IR proteins in all melanoma cell lines after 24 h. This was paralleled by decreased tyrosine phosphorylation of IGF-IR and growth arrest, and, subsequently, massive cell death was observed (this was also seen in BL-41tsp53-2 cells with mutant conformation of ts p53). Taken together, our results suggest that up-regulation of IGF-IR as a result of expression of aberrant p53 may be important for the growth and survival of malignant cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11016658

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia.

Authors:  Jorge Cortes; Hagop Kantarjian; Edward D Ball; John Dipersio; Jonathan E Kolitz; Hugo F Fernandez; Mark Goodman; Gautam Borthakur; Maria R Baer; Meir Wetzler
Journal:  Cancer       Date:  2011-06-29       Impact factor: 6.860

2.  MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents.

Authors:  Martin Monte; Marta Simonatto; Leticia Y Peche; Debora R Bublik; Stefania Gobessi; Marco A Pierotti; Monica Rodolfo; Claudio Schneider
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-17       Impact factor: 11.205

3.  IGF-1R is a molecular determinant for response to p53 reactivation therapy in conjunctival melanoma.

Authors:  Dawei Song; Sonia Cismas; Caitrin Crudden; Eric Trocme; Claire Worrall; Naida Suleymanova; Tingting Lin; Huiyuan Zheng; Stefan Seregard; Ada Girnita; Leonard Girnita
Journal:  Oncogene       Date:  2021-11-17       Impact factor: 9.867

4.  Bcl-2 family proteins and cytoskeleton changes involved in DM-1 cytotoxic effect on melanoma cells.

Authors:  Fernanda Faião-Flores; José Agustín Quincoces Suarez; Vanessa Soto-Cerrato; Margarita Espona-Fiedler; Ricardo Pérez-Tomás; Durvanei Augusto Maria
Journal:  Tumour Biol       Date:  2013-01-23

5.  Insulin-like growth factor-I receptor is suppressed through transcriptional repression and mRNA destabilization by a novel energy restriction-mimetic agent.

Authors:  Po-Chen Chu; Samuel K Kulp; Ching-Shih Chen
Journal:  Carcinogenesis       Date:  2013-07-16       Impact factor: 4.944

6.  Molecular characterization of pediatric gastrointestinal stromal tumors.

Authors:  Narasimhan P Agaram; Michael P Laquaglia; Berrin Ustun; Tianhua Guo; Grace C Wong; Nicholas D Socci; Robert G Maki; Ronald P DeMatteo; Peter Besmer; Cristina R Antonescu
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

7.  Determination of cellular uptake and intracellular levels of Cenersen (Aezea(®), EL625), a p53 antisense oligonucleotide in acute myeloid leukemia cells.

Authors:  Houda Alachkar; Zhiliang Xie; Guido Marcucci; Kenneth K Chan
Journal:  J Pharm Biomed Anal       Date:  2012-08-19       Impact factor: 3.935

Review 8.  Lessons to Learn for Adequate Targeted Therapy Development in Metastatic Colorectal Cancer Patients.

Authors:  Helena Oliveres; David Pesántez; Joan Maurel
Journal:  Int J Mol Sci       Date:  2021-05-09       Impact factor: 5.923

9.  Hwanggeumchal sorghum induces cell cycle arrest, and suppresses tumor growth and metastasis through Jak2/STAT pathways in breast cancer xenografts.

Authors:  Jin Hee Park; Pramod Darvin; Eun Joung Lim; Youn Hee Joung; Dae Young Hong; Eui U Park; Seung Hwa Park; Soo Keun Choi; Eon-Soo Moon; Byung Wook Cho; Kyung Do Park; Hak Kyo Lee; Myong-Jo Kim; Dong-Sik Park; Ill-Min Chung; Young Mok Yang
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

10.  Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor.

Authors:  Leonard Girnita; Ada Girnita; Olle Larsson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-23       Impact factor: 12.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.